Subject: PZOO Issues Game Changing News

SCV Client Spotlight
PZOO Issues Game Changing News
Hot Stock to WatchHot Stock to Watch

Company: Pazoo Inc. (OTCQB: PZOO)

End of Day:

Price: 0.0344

Change (%): + 0.0014 (4.24)

Volume: 2,965,686
PZOO Chart

Pazoo Increases Its Stake in Harris Lee, LLC, a Company Formed to Set Up Medical Marijuana Testing Laboratories in The United States and Canada, To A 55% Controlling Interest

WHIPPANY, NJ / ACCESSWIRE / October 29, 2014 / Pazoo, Inc. (OTCQB: PZOO) (German WKN#: A1J3DK) is pleased to announce it has acquired an additional 10% interest in Harris Lee LLC, for a total controlling interest of 55% in exchange for 150,000 preferred C shares, the equivalent of 15 million restricted common shares, of Pazoo Inc. Harris Lee, LLC was formed to potentially expand marijuana testing lab operations in other states outside of Nevada. The selling owners of Harris Lee, LLC could earn an additional 75,000 preferred C shares upon the opening of testing facilities in any state other than Nevada and a further 75,000 preferred C shares upon the opening of a second testing facility outside of Nevada.

While waiting for a Schedule 1 license from the DEA in order to conduct research using marijuana, Dr. Richard M. Hyslop, Professor of Chemistry and Biochemistry at UNC, along with his colleague Dr. Corina Brown are conducting these preclinical studies using model compounds that are similar chemically to the components they are looking for in Cannabis.

Continue Reading

Top PerformerYesterday's Top Performer

Hinto Energy Inc. (OTCQB: HENI)

End of Day:

Price: 0.50

Change (%): + 0.15 (42.86)

Volume: 11,400
HENI Chart

Hinto Energy, Inc. is involved in the acquisition, production, development and exploration of Oil and Natural Gas properties in the Rocky Mountain Basins. The Company is actively seeking to acquire producing oil and natural gas properties that offer long term production opportunities and properties with proven oil and gas reserves. The Company employs state-of-the-art technology for Reservoir Characterization, discover by-passed reserves, and to evaluate unexploited resources made available with modern horizontal drilling.

Company Information Sheet

Other Small Cap News

Company: Nuvilex, Inc. (OTCQB: NVLX)

Nuvilex, Inc. Engaged in "Cutting Edge" Cannabis Preclinical Studies Using Model Compounds With Cell-in-a-Box

NEW YORK, NY--(Marketwired - October 29, 2014) - Nuvilex, Inc. (OTCQB: NVLX) isn't letting the upcoming mid-term elections or the views in Washington, D.C., on medical marijuana slow down its research. The company is currently engaged in preclinical studies at the University of Northern Colorado (UNC) targeting Cannabis-based cancer treatments using Nuvilex's Cell-in-a-Box® cellulose-based live cell encapsulation technology.

While waiting for a Schedule 1 license from the DEA in order to conduct research using marijuana, Dr. Richard M. Hyslop, Professor of Chemistry and Biochemistry at UNC, along with his colleague Dr. Corina Brown are conducting these preclinical studies using model compounds that are similar chemically to the components they are looking for in Cannabis.

Continue Reading

Company: Plandaí Biotechnology, Inc. (OTCQB: PLPL)

Plandai Biotechnology, Inc. Receives Approval to Grow Cannabis for Medical Research From Uruguay's Ministry of Public Health

SEATTLE, WA--(Marketwired - October 29, 2014) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), a developer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that Uruguay's Ministry of Public Health has approved an academic collaboration between Plandaí and the Group of Medicinal Chemistry from the School of Science at the University of the Republic ("University") in Montevideo, Uruguay. The approval, issued in September 2014, allows Plandaí to grow cannabis in conjunction with the University, for medical research, which will be undertaken by students and scientists from the School of Science at the University.

Plandaí Biotechnology - Uruguay, SA, a wholly owned subsidiary of Plandaí Biotechnology, is currently the only company given authorization to grow cannabis and conduct medical research in Uruguay. Published research indicates that Plandaí's proprietary extraction process should render the complete cannabinoid complex from the live plant while retaining the acid forms of THC, which are devoid of psychotropic effects. The result should be a highly bioavailable extract that retains all of the potential medical benefits of cannabis without the psychoactive properties. Plandaí intends to establish a pharmaceutical platform in once the initial scientific investigations have been successfully completed.

Continue Reading

Market News

By Kate Gibson: CNBC

US stocks mixed before Fed; Facebook tumbles

U.S. stocks opened little moved on Wednesday, a day after the Dow industrials rallied to finish above 17,000 for the first time in three weeks, as Facebook declined and Wall Street awaited a monetary-policy decision from the Federal Reserve.

Facebook shares slid in early New York trading as the social network projected slower revenue growth this quarter and said spending would increase in 2015; Hershey declined after the chocolate maker posted third-quarter earnings below estimates and cut its guidance for the year, and U.S. Steel surged after posting better-than-estimated quarterly results.

Fed officials end a two-day policy meeting Wednesday with the release of a statement at 2 p.m. Eastern. The central bank is expected to announce an end to the bond purchases that helped fuel stock gains and increased the Fed's balance sheet to a record.

Continue Reading

By Jeff Macke:
Yahoo Finance

Markets positive for October ahead of Fed statement

One of the finest traditions on Wall Street is October ripping the hearts out of as many bulls and bears as possible. On that front 2014 will go down as a banner year no matter what happens between now and the close on Friday.

With yesterday's 1.2% rally the S&P 500 is now positive for October. That's right, positive. Since hitting 1,820 on the morning of the 15th the S&P500 has ripped 165 points or 9% in a straight line. The move has everyone groping for a reason. Technicians will point to support holding and buyers coming in when the S&P500 approached "correction" levels. Fundamentally inclined investors are claiming earnings were better than expected.

Of course perma-Bears hate all of this. They'll note, correctly, that earnings are growing more than two times the rate of revenue increases. That's unsustainable and has been for as long as anyone can remember. It should also be mentioned October isn't over yet. Later today the Fed is expected to announce the end of Quantitative Easing and tomorrow brings the latest absurdly rough estimate of GDP for Q3.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the "unsubscribe" link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks